Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study

Aquizerate, A., Laforgue, E.J., Istvan, M., Rousselet, M., Gerardin, M., Jouanjus, E., et al. (2023). French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change. European Journal of Public Health, 33(2), 169–175. https://doi.org/10.1093/eurpub/ckad003/7030751.

Baumevieille, M., Miremont, G., Haramburu, F., Maurain, C., & Begaud, B. (2001). Le système français d’évaluation de la pharmacodépendance et de l’abus : Consécration juridique. Thérapie, 56, 15–22.

CAS  PubMed  Google Scholar 

Code de la Santé Publique (CSP), Sous-section 4 : Centres d’évaluation et d’information sur la pharmacodépendance et d’addictovigilance (Articles R5132–112 à R5132–116) : obligation de déclaration.

Diaz, L., Eiden, C., Jouanjus, E., Frauger, E., Fouilhé, N., Djezzar, S., et al. (2023). Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020. Therapies, 2023. https://linkinghub.elsevier.com/retrieve/pii/S0040595723000306

Haute Autorité de Santé (HAS) Recommandation de bonne pratique. Prise en charge du patient adulte se plaignant d’insomnie en médecine générale 2007, May. https://www.has-sante.fr/jcms/c_522637/fr/prise-en-charge-du-patient-adulte-se-plaignant-d-insomnie-en-medecine-generale.

Holm, K.J., Goa, K.L., Zolpidem. (2022). An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs, 59(4), 865–89. https://doi.org/10.2165/00003495-200059040-00014

Istvan, M., Rousselet, M., Laforgue, E. J., Guerlais, M., Gérardin, M., Jolliet, P., Feuillet, F., & Victorri-Vigneau, C. (2022). Did the pattern of use of zolpidem change since the enforcement of a new prescription rule? A latent class analysis using the French health insurance database. Expert Opinion Drug Safety, 8, 1–10. https://doi.org/10.1080/14740338.2022.2047930

Article  Google Scholar 

Istvan, M., Rousselet, M., Laforgue, EJ., Guerlais, M., Gérardin, M., Jolliet, P., et al. (2022). Did the pattern of use of zolpidem change since the enforcement of a new prescription rule? A latent class analysis using the French health insurance database. Expert Opinion Drug Safety. 8 mars 1–10.

Jouanjus, E., Guernec, G., Lapeyre-Mestre, M., French Addictovigilance Network. (2018). Medical prescriptions falsified by the patients: A 12-year national monitoring to assess prescription drug diversion. Fundamental Clinic Pharmacology, 32(3), 306–322. https://doi.org/10.1111/fcp.12356

Article  CAS  Google Scholar 

Kralic, J.E., Korpi, E.R., O’Buckley, T.K., Homanics, G.E., Morrow, A.L., (2022). Molecular and pharmacological characterization of GABA A receptor α1 subunit knockout mice. Journal of Pharmacology and Experimental Therapeutics, 302(3), 1037–45 (2022). https://doi.org/10.1124/jpet.102.036665

Laforgue, E. J., Istvan, M., Schreck, B., Mainguy, M., Jolliet, P., Grall-Bronnec, M., & Victorri-Vigneau, C. (2022). Perception of the regulatory change for zolpidem prescription by French general practitioners and its relation to prescription behavior. Journal of Clinical Medicine, 11(8), 2176. https://doi.org/10.3390/jcm11082176

Article  PubMed  PubMed Central  Google Scholar 

McKernan, R.M., Rosahl, T.W., Reynolds, D.S., Sur, C., Wafford, K.A., Atack, J.R., et al. (2000). Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype. Nature Neuroscience, 3(6), 587–92. http://www.nature.com/articles/nn0600_587

Olsen, R.W., Sieghart, W. (2008). International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acid A receptors: Classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacological Reviews, 60(3), 243–60 (2008). https://doi.org/10.1124/pr.108.00505

Rousselet, M., Feuillet, F., Gerardin, M., Jolliet, P., Hardouin, J. B., & Victorri-Vigneau, C. (2017). The French addictovigilance network clinical assessment: Z-drugs, true false twins. Expert Opinion on Drug Safety, 16(9), 1063–1069. https://doi.org/10.1080/14740338.2017.1346084

Article  PubMed  Google Scholar 

Rousselot, N., Pariente, A., Mansiaux, Y., & Victorri-Vigneau, C. (2020). Impact of secured prescription implementation for zolpidem on hypnotics use in France: A time-series analysis on national data. Annals of Family Medicine, 18(4), 345–348. https://doi.org/10.1370/afm.2556

Article  PubMed  PubMed Central  Google Scholar 

Roussin, A., Soeiro, T., Fouque, C., Jouanjus, E., Frauger, E., Fouilhé, N., et al. (2022). Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data. British Journal of Clinical Pharmacology, 88(8), 3789–802. https://doi.org/10.1111/bcp.15323

Sabe, M., Kashef, H., Gironi, C., Sentissi, O. (2022). Zolpidem stimulant effect: Induced mania case report and systematic review of cases. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 94, 109643. https://linkinghub.elsevier.com/retrieve/pii/S0278584618308595

Schifano, F., Chiappini, S., Corkery, J.M., Guirguis, A. (2019). An insight into Z-drug abuse and dependence: An examination of reports to the European medicines agency database of suspected adverse drug reactions. International Journal of Neuropsychopharmacology, 22(4), 270–7. https://academic.oup.com/ijnp/article/22/4/270/5306970

Seldenrijk, A., Vis, R., Henstra, M., Ho Pian, K., van Grootheest, D., Salomons, T., et al. (2017). Systematic review of the side effects of benzodiazepines. Nederlands Tijdschrift Voor Geneeskunde, 161, D1052.

CAS  PubMed  Google Scholar 

Site de l’association du réseau fraçias d’addictovigilance (n.d.) www.addictovigilance.fr.

Victorri-Vigneau, C., Basset, G., Bourin, M., Jolliet, P. (2022). Impacts de la nouvelle réglementation du flunitrazépam sur la consommation d’hypnotiques. Therapies, 58(5), 425–30. https://linkinghub.elsevier.com/retrieve/pii/S0040595716301263

Victorri-Vigneau, C., Dailly, E., Veyrac, G., Jolliet, P. (2007). Evidence of zolpidem abuse and dependence: Results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. British Journal of Clinical Pharmacology, 64(2), 198–209. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000636/

Victorri-Vigneau, C., Feuillet, F., Wainstein, L., Grall-Bronnec, M., Pivette, J., Chaslerie, A., et al. (2022). Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. European Journal of Clinical Pharmacology, 69(11), 1965–72. https://doi.org/10.1007/s00228-013-1557-x

Victorri-Vigneau, C., Gérardin, M., Rousselet, M., Guerlais, M., Grall-Bronnec, M., & Jolliet, P. (2014). An update on zolpidem abuse and dependence. Journal of Addiction Disorder, 33(1), 15–23. https://doi.org/10.1080/105508872014882725.

留言 (0)

沒有登入
gif